TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27980782

Group type: EXPERIMENTAL
Intervention: Whole genome prediction methods
Number of subjects: 832

Group type: EXPERIMENTAL
Intervention: Whole genome prediction methods with additional demographic covariates
Number of subjects: 832

Group type: EXPERIMENTAL
Intervention: Whole genome prediction methods with SNP-prioritization
Number of subjects: 832
Study: 27980787

Group type: EXPERIMENTAL
Intervention: Group training program based on cognitive-behavioral principles and skills from Dialectical Behavior Therapy (DBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 27980877

Group type: EXPERIMENTAL
Intervention: Suprachoroidal injection of 4-mg triamcinolone acetonide (TA) in 100 μL
Number of subjects: 9
Study: 27981865

Group type: EXPERIMENTAL
Intervention: Idarucizumab
Number of subjects: 90
Study: 27982165

Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation (zinc)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Nutritional evaluations (anthropometric measurements)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Serum albumin and zinc measurements
Number of subjects: 14

Group type: COMPARATOR
Intervention: Lymphocyte count on the 1st day
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Lymphocyte counts and zinc concentrations
Number of subjects: 14
Study: 27984247

Group type: EXPERIMENTAL
Intervention: Dynamic Ultrasound-Guided Short-Axis Needle Tip Navigation Technique
Number of subjects: 100
Study: 27986363

Group type: EXPERIMENTAL
Intervention: FOLFOXIRI plus bevacizumab
Number of subjects: 205
Study: 27986651

Group type: EXPERIMENTAL
Intervention: Alirocumab (150 mg, 5 doses, 2 weeks apart)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 27986796

Group type: EXPERIMENTAL
Intervention: Circumferential dysfunction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Traditional CVD risk factors and elevated HbA
Number of subjects: 0
Study: 27988497

Group type: EXPERIMENTAL
Intervention: Moderately reduced kidney function (eGFR 30 to 60 mL/min per 1.73 m²)
Number of subjects: 13102

Group type: COMPARATOR
Intervention: Normal kidney function (eGFR >60 mL/min per 1.73 m²)
Number of subjects: 13102
Study: 27989041

Group type: EXPERIMENTAL
Intervention: PMVR (MitraClip device)
Number of subjects: 26
Study: 27989576

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 132030

Group type: COMPARATOR
Intervention: HIV-positive adults (not on ART)
Number of subjects: 132030

Group type: COMPARATOR
Intervention: HIV-positive adults in west Uganda
Number of subjects: 132030

Group type: COMPARATOR
Intervention: HIV-positive adults in east Uganda
Number of subjects: 132030

Group type: COMPARATOR
Intervention: HIV-positive adults in Kenya
Number of subjects: 132030

Group type: COMPARATOR
Intervention: Serodiscordant couples in Uganda
Number of subjects: 132030

Group type: COMPARATOR
Intervention: Serodiscordant couples in Kenya
Number of subjects: 132030
Study: 27989789

Group type: EXPERIMENTAL
Intervention: Very high rate cutoff programming (VH-RATE group: monitor zone 170-219 beats/min; ventricular fibrillation zone ≥220 beats/min with 13 ± 4 detection intervals)
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Very high rate cutoff programming (VH-RATE group)
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Control group (programmed with 1 or 2 therapy zones)
Number of subjects: 2000
Study: 27989885

Group type: EXPERIMENTAL
Intervention: Transcaval access for TAVR
Number of subjects: 100
Study: 27989886

Group type: EXPERIMENTAL
Intervention: 40 mg of rosuvastatin daily for 8 to 12 weeks
Number of subjects: 85
Study: 27992268

Group type: EXPERIMENTAL
Intervention: Rituximab induction followed by consolidation
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Rituximab consolidation
Number of subjects: 152

Group type: COMPARATOR
Intervention: CHOP chemotherapy
Number of subjects: 152
Study: 27992451

Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg BID with Vinorelbine 30 mg/m2 IV days 1,8 every 21 days
Number of subjects: 27
Study: 27992493

Group type: EXPERIMENTAL
Intervention: T1.5DM
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: T2DM
Number of subjects: 140
Study: 27992691

Group type: EXPERIMENTAL
Intervention: Triple therapy (MTX plus sulfasalazine plus hydroxychloroquine)
Number of subjects: 157

Group type: COMPARATOR
Intervention: MTX plus infliximab
Number of subjects: 157
Study: 27993231

Group type: EXPERIMENTAL
Intervention: Bipolar Disorder (BD)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: High-Risk (HR)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Low-Risk (LR)
Number of subjects: 99
Study: 27993573

Group type: COMPARATOR
Intervention: Blood-based age/sex/gene expression score (ASGES) low (ASGES ≤15)
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: Blood-based age/sex/gene expression score (ASGES) elevated (ASGES >15)
Number of subjects: 566
Study: 27993904

Group type: EXPERIMENTAL
Intervention: CPET after treatment of iliofemoral occlusive arterial disease
Number of subjects: 30

Group type: COMPARATOR
Intervention: CPET before treatment of iliofemoral occlusive arterial disease
Number of subjects: 30
Study: 27993903

Group type: EXPERIMENTAL
Intervention: Stepwise two-photon excited melanin fluorescence
Number of subjects: 620
Study: 27993926

Group type: EXPERIMENTAL
Intervention: Oxidized LDL (ox-LDL) quartiles (2nd, 3rd, and 4th)
Number of subjects: 3987

Group type: EXPERIMENTAL
Intervention: Oxidized LDL (ox-LDL)
Number of subjects: 3987

Group type: COMPARATOR
Intervention: HOMA-IR (HOMA-insulin resistance)
Number of subjects: 3987
Study: 27995182

Group type: EXPERIMENTAL
Intervention: Colonoscopy Progression Score (CoPS) assessment
Number of subjects: 0
Study: 27995485

Group type: EXPERIMENTAL
Intervention: 5-FU 0.5%/salicylic acid 10%
Number of subjects: 166

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 166
Study: 27995580

Group type: EXPERIMENTAL
Intervention: Olaratumab in combination with doxorubicin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Olaratumab
Number of subjects: 0
Study: 27996967

Group type: EXPERIMENTAL
Intervention: AdhAQP1 administration
Number of subjects: 5
Study: 27997989

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention program (diet and moderate exercise) for 16 weeks
Number of subjects: 16
Study: 27998223

Group type: EXPERIMENTAL
Intervention: Blinatumomab
Number of subjects: 93
Study: 27998970

Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m2 on day 1, Cisplatin 50 mg/m2 on day 2, Veliparib escalating doses from 50 to 400 mg orally two times daily on days 1-7
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Paclitaxel and Cisplatin with Veliparib
Number of subjects: 34
Study: 27999035

Group type: EXPERIMENTAL
Intervention: Intravenous intermittent dosing (ID) of vancomycin
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Continuous dosing (CD) of vancomycin
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Vancomycin therapy (general)
Number of subjects: 32
Study: 27999038

Group type: EXPERIMENTAL
Intervention: ABX464 (50, 100, 150 or 200 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: ABX464
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: ABX464-NGlc
Number of subjects: 24
Study: 27999040

Group type: EXPERIMENTAL
Intervention: Cefazolin administered before surgical incision, before cessation of CPB, and after surgery.
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Cefazolin dosing regimen with an additional bolus dose at the start of CPB.
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Cefazolin dosing regimen during prolonged surgery with preserved renal function.
Number of subjects: 56
Study: 27999607

Group type: EXPERIMENTAL
Intervention: Loquat Leaf Extract (500 mg, 50.94 mg of Ursolic Acid)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 27999663

Group type: EXPERIMENTAL
Intervention: Goal-Directed Fluid Therapy (GDFT)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control group (historical matched patients)
Number of subjects: 130
Study: 27999670

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy group treatment
Number of subjects: 47
Study: 28000140

Group type: EXPERIMENTAL
Intervention: Flash glucose-sensing technology
Number of subjects: 224

Group type: COMPARATOR
Intervention: Self-monitoring of blood glucose (SMBG)
Number of subjects: 224
Study: 28000190

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT) combined with soluble dietary fiber (pectin, 8 g/d) and probiotics (bifid triple viable capsules, twice per day) for 4 weeks after initial treatment with vancomycin 500 mg orally twice per day for 3 days.
Number of subjects: 23
Study: 28000375

Group type: EXPERIMENTAL
Intervention: iDXA
Number of subjects: 93

Group type: COMPARATOR
Intervention: MRI
Number of subjects: 93
Study: 28003133

Group type: EXPERIMENTAL
Intervention: Myofascial induction (MI) intervention focused on the upper limb area following the Pilat approach, 30 minutes per session.
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo pulsed shortwave therapy (control group), 30 minutes per session.
Number of subjects: 21
Study: 28003218

Group type: EXPERIMENTAL
Intervention: Programmatic early treatment success
Number of subjects: 1333

Group type: EXPERIMENTAL
Intervention: Investigator-assessed early treatment success
Number of subjects: 1333
Study: 28003248

Group type: EXPERIMENTAL
Intervention: Nurse-facilitated, mobile phone-based clinical decision support system-enabled intervention
Number of subjects: 6797
Study: 28003301

Group type: EXPERIMENTAL
Intervention: Sublingual video-microscopy
Number of subjects: 15
Study: 28004304

Group type: EXPERIMENTAL
Intervention: Vertical Sleeve Gastrectomy (VSG)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Roux-en-Y Gastric Bypass (RYGB)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Weight-stable controls
Number of subjects: 64
Study: 28004360

Group type: EXPERIMENTAL
Intervention: Minimally invasive adipose graft transposition procedure (mi-AGTP) by thoracoscopy
Number of subjects: 0
Study: 28005959

Group type: EXPERIMENTAL
Intervention: P-TIV (Proteosome-adjuvanted trivalent inactivated influenza vaccine) - 1 x 30 μg, 2 x 30 μg, 2 x 15 μg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: P-TIV (Proteosome-adjuvanted trivalent inactivated influenza vaccine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: P-TIV (Proteosome-adjuvanted trivalent inactivated influenza vaccine) - 2 doses vs 1 dose
Number of subjects: 0
Study: 28006063

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection (2 mg) every 8 weeks after 5 monthly doses with sham injections on nontreatment visits starting at week 24.
Number of subjects: 109

Group type: COMPARATOR
Intervention: Laser control (no treatment).
Number of subjects: 109
Study: 28007027

Group type: EXPERIMENTAL
Intervention: Combination therapy with vancomycin-loaded calcium sulfate and vancomycin-loaded PMMA
Number of subjects: 51

Group type: COMPARATOR
Intervention: Antibiotic-loaded PMMA (Control Group)
Number of subjects: 51
Study: 28007090

Group type: EXPERIMENTAL
Intervention: Allergen challenge chamber (ACC) exposure to ragweed pollen (RW)
Number of subjects: 201
Study: 28007445

Group type: EXPERIMENTAL
Intervention: Home-based, person-directed, structured program delivered by an interprofessional team (occupational therapist, registered nurse, handyman)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Home-based, person-directed, structured program delivered by an interprofessional team
Number of subjects: 226
Study: 28007690

Group type: EXPERIMENTAL
Intervention: DTI tractography-assisted stereotactic surgery targeting the DRT in general anesthesia
Number of subjects: 24

Group type: COMPARATOR
Intervention: Stereotactic surgery of the thalamic/subthalamic region as conventionally used
Number of subjects: 24
Study: 28007741

Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound-guided drug-eluting stents implantation with ASM
Number of subjects: 2072

Group type: COMPARATOR
Intervention: Intravascular ultrasound-guided drug-eluting stents implantation without ASM
Number of subjects: 2072
Study: 28008698

Group type: EXPERIMENTAL
Intervention: Patients recorded in primary care (PC) but never hospitalized
Number of subjects: 89554

Group type: EXPERIMENTAL
Intervention: Patients in hospital admissions but not known in PC
Number of subjects: 89554

Group type: EXPERIMENTAL
Intervention: Patients known in both contexts (PC and hospital admissions)
Number of subjects: 89554

Group type: COMPARATOR
Intervention: General population (age- and sex-matched)
Number of subjects: 89554
Study: 28009526

Group type: EXPERIMENTAL
Intervention: Transient Thelarche (TT)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Normal progression
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: First (transient) thelarche
Number of subjects: 98
Study: 28009745

Group type: EXPERIMENTAL
Intervention: Minimally invasive inguinal lymph node dissection (MILND)
Number of subjects: 87
Study: 28010726

Group type: EXPERIMENTAL
Intervention: Anti-TNF treatment
Number of subjects: 25
Study: 28011051

Group type: EXPERIMENTAL
Intervention: Neoadjuvant temozolomide (TMZ) at a daily dose of 75 mg/m²
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Neoadjuvant temozolomide (TMZ)
Number of subjects: 50
Study: 28011397

Group type: EXPERIMENTAL
Intervention: 3-methoxy-catalposide
Number of subjects: 0
Study: 28011608

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment for Mycobacterium abscessus lung disease
Number of subjects: 67
Study: 28011903

Group type: EXPERIMENTAL
Intervention: Obinutuzumab plus bendamustine
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Obinutuzumab plus CHOP
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Obinutuzumab maintenance therapy
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Adverse events during induction
Number of subjects: 81
Study: 28012074

Group type: EXPERIMENTAL
Intervention: Adjustable mitral annuloplasty ring
Number of subjects: 45
Study: 28012300

Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavior therapy (ICBT)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 84
Study: 28012677

Group type: EXPERIMENTAL
Intervention: Lenalidomide plus dexamethasone
Number of subjects: 100
Study: 28012848

Group type: EXPERIMENTAL
Intervention: Fluorescently labeled peptide (76.4 μmol/L) administered topically to proximal colon
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Fluorescently labeled peptide (2.25 μmol/L and 76.4 μmol/L) administered topically to proximal colon
Number of subjects: 63

Group type: COMPARATOR
Intervention: Fluorescently labeled peptide
Number of subjects: 63
Study: 28013265

Group type: EXPERIMENTAL
Intervention: High drug exposure to Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Low drug exposure to Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC)
Number of subjects: 101
Study: 28013354

Group type: EXPERIMENTAL
Intervention: High GABA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-selective GABA
Number of subjects: 0
Study: 28013405

Group type: EXPERIMENTAL
Intervention: D2C7-(scdsFv)-PE38KDEL (D2C7-IT) administered via intratumoral convection-enhanced delivery for 72 hours.
Number of subjects: 0
Study: 28013450

Group type: EXPERIMENTAL
Intervention: abiliti® closed-loop GES system (CLGES)
Number of subjects: 97
Study: 28017350

Group type: EXPERIMENTAL
Intervention: hs-cTnT ≥ 14 ng/l
Number of subjects: 1279

Group type: COMPARATOR
Intervention: hs-cTnT < 14 ng/l, overweight
Number of subjects: 1279

Group type: COMPARATOR
Intervention: hs-cTnT < 14 ng/l, obese
Number of subjects: 1279

Group type: COMPARATOR
Intervention: hs-cTnT ≥ 14 ng/l, overweight
Number of subjects: 1279

Group type: COMPARATOR
Intervention: hs-cTnT ≥ 14 ng/l, obese
Number of subjects: 1279
Study: 28017384

Group type: EXPERIMENTAL
Intervention: Cardiac magnetic resonance (CMR) imaging
Number of subjects: 203
Study: 28017714

Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 134

Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 134
Study: 28017967

Group type: EXPERIMENTAL
Intervention: Duvelisib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Duvelisib and Venetoclax combination
Number of subjects: 0
Study: 28018669

Group type: EXPERIMENTAL
Intervention: Omeprazole-clopidogrel combination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pantoprazole-clopidogrel combination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clopidogrel alone
Number of subjects: 0
Study: 28018871

Group type: EXPERIMENTAL
Intervention: Intervention including self-management support and patient-centred motivational approaches
Number of subjects: 332
Study: 28025328

Group type: EXPERIMENTAL
Intervention: Mutations in BOREALIN gene (p.S148F, p.R114Q, p.L177W)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Expression of BOREALIN mutants in human thyrocytes
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Gene expression pattern in thyroid tissue of patient with BOREALIN-p.R114W
Number of subjects: 134
Study: 28025359

Group type: EXPERIMENTAL
Intervention: Peer-supported self-management intervention (IMPPRESS)
Number of subjects: 26
Study: 28025627

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 28025928

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care using the Dader Method
Number of subjects: 92

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 92
Study: 28027590

Group type: EXPERIMENTAL
Intervention: Entecavir
Number of subjects: 62
Study: 28027850

Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI)
Number of subjects: 136

Group type: COMPARATOR
Intervention: MRI before PCI
Number of subjects: 136
Study: 28028584

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF)
Number of subjects: 538

Group type: COMPARATOR
Intervention: Sinus rhythm
Number of subjects: 538
Study: 28029055

Group type: EXPERIMENTAL
Intervention: Combination of hsTnT, NT-proBNP, and hsCRP with the GRACE score
Number of subjects: 1892

Group type: COMPARATOR
Intervention: Conventional versus high sensitivity troponin assay
Number of subjects: 1892

Group type: COMPARATOR
Intervention: Novel biomarkers (PlGF, sFlt-1, sFlt-1/PlGF ratio)
Number of subjects: 1892

Group type: EXPERIMENTAL
Intervention: All-cause mortality at 30 days
Number of subjects: 1892

Group type: EXPERIMENTAL
Intervention: All-cause mortality at 1 year
Number of subjects: 1892
Study: 28029383

Group type: EXPERIMENTAL
Intervention: M-BET (multicomponent behavioral treatment and exercise therapy)
Number of subjects: 72

Group type: COMPARATOR
Intervention: α-blocker (tamsulosin, 0.4-mg tablet nightly)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Combination therapy (M-BET + α-blocker)
Number of subjects: 72
Study: 28029529

Group type: EXPERIMENTAL
Intervention: Ledipasvir (90 mg) plus sofosbuvir (400 mg) fixed-dose combination tablet once daily for 6 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ledipasvir plus sofosbuvir
Number of subjects: 20
Study: 28029746

Group type: EXPERIMENTAL
Intervention: Alström syndrome cohort
Number of subjects: 38
Study: 28029918

Group type: EXPERIMENTAL
Intervention: Selumetinib (20 to 30 mg/m², administered twice daily on a continuous dosing schedule in 28-day cycles)
Number of subjects: 24
Study: 28029927

Group type: EXPERIMENTAL
Intervention: Chimeric antigen receptor (CAR)-engineered T cells targeting IL13Rα2, administered multiple times over 220 days through intracranial delivery routes.
Number of subjects: 1
Study: 28030441

Group type: EXPERIMENTAL
Intervention: Permissive hypoxaemia during ECMO
Number of subjects: 7
Study: 28030555

Group type: EXPERIMENTAL
Intervention: In-bed cycling (30 minutes, 6 days/week)
Number of subjects: 33
Study: 28030578

Group type: EXPERIMENTAL
Intervention: Simple non-invasive tools including ECG, NT-proBNP, SO2, and WHO functional class I-II
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Combination of non-right axis deviation, NT-proBNP<333pg/ml, SO2≥95.5%, and WHO functional class I-II
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Simple non-invasive tools
Number of subjects: 394
Study: 28030579

Group type: EXPERIMENTAL
Intervention: Faldaprevir 120 mg and Deleobuvir 600 mg (Child-Pugh A) or 400 mg (Child-Pugh B) twice-daily with weight-based ribavirin for 24 weeks
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Faldaprevir + Deleobuvir + Ribavirin
Number of subjects: 35
Study: 28031192

Group type: EXPERIMENTAL
Intervention: Healthy Eating Index (HEI) 2010
Number of subjects: 1336

Group type: EXPERIMENTAL
Intervention: Alternate Mediterranean Diet Score (aMED)
Number of subjects: 1336

Group type: EXPERIMENTAL
Intervention: WHO Healthy Diet Indicator (HDI)
Number of subjects: 1336

Group type: EXPERIMENTAL
Intervention: Baltic Sea Diet (BSD)
Number of subjects: 1336
Study: 28031267

Group type: EXPERIMENTAL
Intervention: Plasmodium falciparum Preerythrocytic Antigen UIS3
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 28031277

Group type: EXPERIMENTAL
Intervention: Cardiac implantable electronic device (CIED)
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF) burden ≥5 min
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: History of CABG
Number of subjects: 489
Study: 28031392

Group type: EXPERIMENTAL
Intervention: DCE-MRI assessment of blood-brain barrier (BBB) permeability changes
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Follow-up examination on day 5-7
Number of subjects: 54
Study: 28031423

Group type: EXPERIMENTAL
Intervention: Bidirectional Glenn (BDG)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Fontan
Number of subjects: 168

Group type: COMPARATOR
Intervention: Pre-BDG
Number of subjects: 168
Study: 28031441

Group type: EXPERIMENTAL
Intervention: Modular neutrophil signature (upregulation of module M5.15) in SLE patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: M5.15 activity in patients responding to treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: M5.15 activity in quiescent patients with a past history of LN
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: M5.15 activation in patients with bacterial sepsis or ANCA-associated vasculitis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: M5.15 activation overall
Number of subjects: 0
Study: 28031749

Group type: EXPERIMENTAL
Intervention: Intragastric balloon (IGB) treatment for 6 months
Number of subjects: 50
Study: 28031816

Group type: EXPERIMENTAL
Intervention: Ipilimumab at 3 mg/kg with peginterferon alfa-2b at 2 μg/kg/week
Number of subjects: 31